Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Accumulated Expenses (2018 - 2025)

Dna X's Accumulated Expenses history spans 8 years, with the latest figure at $704000.0 for Q4 2025.

  • Quarterly results put Accumulated Expenses at $704000.0 for Q4 2025, up 181.6% from a year ago — trailing twelve months through Dec 2025 was $704000.0 (up 181.6% YoY), and the annual figure for FY2025 was $704000.0, up 181.6%.
  • Accumulated Expenses for Q4 2025 was $704000.0 at Dna X, down from $13.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $23.1 million in Q3 2024 to a low of $250000.0 in Q4 2024.
  • The 5-year median for Accumulated Expenses is $8.2 million (2021), against an average of $7.5 million.
  • Peak annual rise in Accumulated Expenses hit 5815.09% in 2024, while the deepest fall reached 97.97% in 2024.
  • Year by year, Accumulated Expenses stood at $836000.0 in 2021, then soared by 1178.95% to $10.7 million in 2022, then grew by 15.04% to $12.3 million in 2023, then tumbled by 97.97% to $250000.0 in 2024, then skyrocketed by 181.6% to $704000.0 in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $704000.0, $13.6 million, and $12.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.